MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen DSO Ratio 2011-2026 | OPGN
Annual DSO Ratio OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.66 | 33 | 118 | 77.4 | 56.6 | 322 | 46.3 | 92 | 49.2 | 78.4 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 322 | 4.66 | 87.8 |
Quarterly DSO Ratio OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 46.5 | - | - | - | - | - | - | 68 | 79.7 | 59 | - | 143 | 47.4 | 140 | - | 45 | 53.9 | 62.6 | - | 56.4 | 50.1 | 90.3 | - | 79.9 | 51.3 | 42.1 | - | 61.8 | 43.2 | 63.8 | - | 99.1 | 105 | 79.9 | - | 65.2 | 41.9 | 51.8 | - | 63.1 | 165 | 114 | - | 55.1 | 42.9 | 21 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 165 | 21 | 70.6 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
31.7 | $ 16.65 | - | $ 179 M |  China |
|
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
49.2 | $ 23.93 | -3.12 % | $ 665 M |  USA |
 |
Agilent Technologies
A
|
63.8 | $ 113.27 | -1.39 % | $ 34.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
Neogen Corporation
NEOG
|
66.6 | $ 9.11 | -2.52 % | $ 1.98 B | USA |
 |
Co-Diagnostics
CODX
|
94.7 | $ 1.59 | -2.72 % | $ 2.12 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 5.26 | -4.36 % | $ 312 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 19.91 | -9.15 % | $ 1.06 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 14.9 | -2.61 % | $ 451 M | USA |
 |
Illumina
ILMN
|
61.3 | $ 124.12 | -2.21 % | $ 19.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Trinity Biotech plc
TRIB
|
87.2 | $ 0.61 | -1.21 % | $ 61.9 M |  Irlanda |
 |
Charles River Laboratories International
CRL
|
65 | $ 168.25 | 0.88 % | $ 8.34 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
Twist Bioscience Corporation
TWST
|
44.5 | $ 57.54 | -2.72 % | $ 3.44 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
46.1 | $ 82.57 | -0.66 % | $ 10.4 B | USA |
 |
Lantheus Holdings
LNTH
|
80.5 | $ 80.89 | -3.18 % | $ 5.46 B | USA |
 |
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
66.9 | $ 1.96 | 1.5 % | $ 8.67 M | USA |
 |
Senseonics Holdings
SENS
|
10.3 | $ 6.86 | -4.44 % | $ 286 M | USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
50.4 | $ 410.67 | 0.22 % | $ 11.8 B | USA |
 |
Biomerica
BMRA
|
57.7 | $ 2.16 | -1.47 % | $ 4.96 M | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K |  Israel |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 114.53 | 11.74 % | $ 9.45 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 255.97 | -1.39 % | $ 21.3 B | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 9.18 | 1.72 % | $ 1.18 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 15.0 | -10.93 % | $ 336 M | USA |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.75 | -1.96 % | $ 440 M | USA |
 |
Natera
NTRA
|
81.5 | $ 194.2 | -2.98 % | $ 19.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 188.26 | -3.48 % | $ 20.9 B | USA |
 |
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | USA |
 |
Exagen
XGN
|
51.2 | $ 2.73 | - | $ 58.9 M | USA |